UPDATE: (NASDAQ:GOVX) has moved up 100% from this mornings trading surge. on 355,000 plus shares and increasing. Shares currently at $2.82 a share

UPDATE: (NASDAQ:GOVX) has moved up 100% from this mornings trading surge. on 355,000 plus shares and increasing. Shares currently at $2.82 a share

(NASDAQ:GOVX) shares are up more than 18% this morning, on 19,000 plus trades at around $1.65 a share in the pre-market. Company is a vaccine play and has risen on recent news

GeoVax Announces Upcoming Presentations at Scientific Conferences

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.

  • 2022 National Biotechnology Conference, Anaheim, CA, May 9-12

On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic Prophylactics to Address Evolving SARS-CoV-2 Variants. Dr. Hauser will discuss the importance of T cell immunity to conserved viral epitopes amid the backdrop of rapid viral evolution.

  • Genetic Vaccine Development for Infectious Disease Summit, Boston, MA, May 24-26

On May 26, Don Diamond, PhD, professor in City of Hope’s Department of Hematology & Hematopoietic Transplantation, and the lead original developer of GeoVax’s vaccine against COVID-19 (GEO-CM04S1, formerly known as COH04S1) currently being evaluated in two Phase 2 clinical trials, will deliver a presentation titled, Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2.

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist